Premium
BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families
Author(s) -
Azzouzi AbdelRahene,
StoppaLyonnet Dominique,
Roupret Morgan,
Larre Stéphane,
Mangin Philippe,
Cussenot Oliver
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2006.01712.x
Subject(s) - medicine , prostate cancer , breast cancer , prostate , mutation , genetic counseling , brca2 protein , oncology , cancer , genetic testing , phenotype , gene , germline mutation , genetics , biology
It is known that in some families an association exists between breast and prostate cancer. Several reports have suggested that BRCA2 mutations may be associated with an increased risk of these cancers. Herein, we report three cases of early onset of prostate cancer in families with female and male breast cancers. In each case, the familial phenotype is associated with a mutation of the BRCA2 gene. More generally, genetic counseling, including screening for BRCA2 mutations, should become standard practice in kindred with prostate and breast cancers.